Brutalist Biotech

• The next generation of pulsed field ablation takes the stage at HRS annual meeting (2d)
• ALX Oncology doubles down on lead CD47 inhibitor after asset fails two midstage cancer trials (2d)
• HHS reverses course, says long-running women’s health study will retain funding (2d)

• Biohaven stock slides on withdrawal of European marketing application (2d)
• Gilead leans on HIV drugs as oncology sales slow (2d)
• Halozyme sues Merck; FDA blames cuts for Vanda delay (2d)

• J&J reports durability data for bladder cancer 'pretzel' drug (1d)
• Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more (1d)
• FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill (2d)

• Caribou Changes Course Again, Lays Off 32% of Workforce (2d)
• Fact or Fiction? Unpacking FDA Commissioner Marty Makary’s First Interviews (2d)
• AbbVie Lambasts Trump’s Drug Pricing Proposal, Deflects Tariff Concerns (2d)

Bio IT World

• Advancing Precision Medicine with Ethical AI and Standardized Data (2d)
• Tech Veteran Chris Dwan Challenges Life Sciences to Build Infrastructure, Businesses Strategically (4d)
• AI in Drug Development: Promise and Pitfalls (5d)

• U.S. health officials inject new uncertainty into approval process for Covid boosters (1h)
• ‘Fight for your science’: Researchers urged to speak out at AACR (3h)
• Taking science’s temperature at the annual AACR meeting (1d)

• NHS Wales Pilots Paige AI Tool to Triage Cancer Cases (3d)
• Novotech Report: Over 800 Global IPF Trials Since 2020, Led by Asia-Pacific (3d)
• Immunai and Parker Institute to Build Largest Single-Cell Dataset for Real-World Immunotherapy Research (3d)

• The past, present, and future of genome sequencing (2d)
• AI in biotech today, and how it will impact the industry tomorrow (2d)
• 21 UK biotech companies you should know about (3d)

• StockWatch: Tools Giants Foresee Revenue Impacts from Tariffs, Job Cuts (4h)
• Navigating Biotech’s New Normal, AI to Engineer Cas9 Enzymes, and Sequencing Generations (2d)
• BioSkryb and Tecan Introduce Single-Cell Multiomics Workflow (2d)

• Healer, Mentor and Leader (6h)
• Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models (6h)
• FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors (1d)

Contract Pharma*

• FDA Approves Akeso’s Penpulimab for Nasopharyngeal Carcinoma (2d)
• CPTx Appoints McDavid Stilwell as Chief Financial Officer (3d)
• BMS Pays Evotec $75M for Molecular Glue Research Progress (3d)

• Acoramidis approved for heart condition treatment (2d)
• Genomics study launches to optimise childhood cancer care in Ireland (3d)
• UCL researchers launch congenital muscular dystrophy research programme (4d)

• Bringing Patient Data to the Frontlines: Why Interoperability Must Include EMS (9h)
• Hospitals Are Freezing M&A Deals as Federal Policies Rattle Industry (10h)
• Novo Nordisk Notches a Court Win Against Wegovy and Ozempic Compounders (10h)

• US halts funding for new COVID-19 vaccines (2d)
• OxyVinyls will contribute to the $600 million settlement in the East Palestine train derailment case (2d)
• Grove Biopharma launches to develop therapeutic protein-like polymers (2d)

The Pharma Letter*

• The week in pharma: action, reaction and insight – week to April 25 (13h)
• Amgen announces $900 million production investment (1d)
• MHRA nod for Bayer’s Beyonttra for ATTR-CM (1d)

• SunRISe-1 Cohort 4: Promising TAR-200 Outcomes in Papillary NMIBC (3h)
• Bladder Cancer Takes Center Stage With Breakthrough Advancements at AUA 2025 (7h)
• KEYNOTE-689 Trial of Pembrolizumab Shows Promising EFS in LA-HNSCC (7h)

• Analyst predicts trouble ahead for GN: Trade war could derail transformation (2d)
• SSI Diagnostica increases US footprint with another acquisition (2d)
• More obesity companies want to compete on healthy weight loss and solving "ethical challenge" (2d)

• What's Going On In Water Droplets (2d)
• A New Glioblastoma Treatment (3d)
• Streptomycin For Metastatic Cancer (5d)

• Ozempic patient blinded by NAION sues Novo Nordisk (2d)
• Akeso PD-1 inhibitor cleared as Keytruda challenger advances (2d)
• AbbVie files fast-acting Botox successor in US (2d)

• Partners sign deal to build largest multimodal oncology foundation model (2d)
• This week in drug discovery (21-25 April) (2d)
• UMass joins Phase II trial for multiple sclerosis (2d)

Google News Biotech

• Injectable Male Birth Control Effective for at Least 2 Years, Says Biotech Startup - Gizmodo (10h)
• Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks - WSJ (13h)
• Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks - Yahoo Finance (13h)